NO992804L - Benzodioksol-, benzofuran-, dihydrobenzofuran- og benzodioksan-melatonergiske midler - Google Patents

Benzodioksol-, benzofuran-, dihydrobenzofuran- og benzodioksan-melatonergiske midler

Info

Publication number
NO992804L
NO992804L NO992804A NO992804A NO992804L NO 992804 L NO992804 L NO 992804L NO 992804 A NO992804 A NO 992804A NO 992804 A NO992804 A NO 992804A NO 992804 L NO992804 L NO 992804L
Authority
NO
Norway
Prior art keywords
benzodioxane
benzodioxole
dihydrobenzofuran
benzofuran
melatonergic agents
Prior art date
Application number
NO992804A
Other languages
English (en)
Other versions
NO321450B1 (no
NO992804D0 (no
Inventor
John D Catt
Graham Johnson
Daniel J Keavy
Ronald J Mattson
Michael F Parker
Katherine S Takaki
Joseph P Yevich
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO992804D0 publication Critical patent/NO992804D0/no
Publication of NO992804L publication Critical patent/NO992804L/no
Publication of NO321450B1 publication Critical patent/NO321450B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Adhesives Or Adhesive Processes (AREA)
NO19992804A 1996-12-10 1999-06-09 Benzodioksol-, benzofuran-, dihydrobenzofuran- og benzodioksan-derivater som kan anvendes som melatonergiske midler og anvendelse av disse for fremstilling av farmasoytiske preparater NO321450B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3268996P 1996-12-10 1996-12-10
PCT/US1997/022627 WO1998025606A1 (en) 1996-12-10 1997-12-09 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents

Publications (3)

Publication Number Publication Date
NO992804D0 NO992804D0 (no) 1999-06-09
NO992804L true NO992804L (no) 1999-08-09
NO321450B1 NO321450B1 (no) 2006-05-15

Family

ID=21866306

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992804A NO321450B1 (no) 1996-12-10 1999-06-09 Benzodioksol-, benzofuran-, dihydrobenzofuran- og benzodioksan-derivater som kan anvendes som melatonergiske midler og anvendelse av disse for fremstilling av farmasoytiske preparater

Country Status (26)

Country Link
US (3) US5856529A (no)
EP (1) EP1027043B1 (no)
JP (1) JP4290765B2 (no)
KR (1) KR100499106B1 (no)
CN (1) CN1152679C (no)
AR (1) AR010346A1 (no)
AT (1) ATE281833T1 (no)
AU (1) AU719994B2 (no)
BR (1) BR9713690B1 (no)
CA (1) CA2274183C (no)
CY (1) CY2501B1 (no)
CZ (1) CZ297673B6 (no)
DE (1) DE69731562T2 (no)
DK (1) DK1027043T3 (no)
ES (1) ES2230626T3 (no)
HK (1) HK1029947A1 (no)
HU (1) HU226524B1 (no)
IL (1) IL129999A (no)
NO (1) NO321450B1 (no)
NZ (1) NZ335910A (no)
PL (1) PL190499B1 (no)
PT (1) PT1027043E (no)
RU (1) RU2190609C2 (no)
TW (1) TW476758B (no)
WO (1) WO1998025606A1 (no)
ZA (1) ZA9711051B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
US6214869B1 (en) 1998-06-05 2001-04-10 Bristol-Myers Squibb Heterocyclic cis cyclopropane derivatives as melatonergic agents
ATE257834T1 (de) * 1999-06-30 2004-01-15 Bristol Myers Squibb Co Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
PL208074B1 (pl) 2001-05-15 2011-03-31 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych oksazolu
MXPA04003087A (es) * 2001-10-04 2004-09-06 Wyeth Corp Derivados de cromano como ligados de 5-hidroxitriptamina-6.
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
BR0312452A (pt) * 2002-07-03 2005-04-19 Hoffmann La Roche Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; e método para o tratamento e/ou profilaxia de doenças que são moduladas por agonistas de ppar(alfa) e/ou ppar(gama)
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
KR100645684B1 (ko) * 2002-09-12 2006-11-15 에프. 호프만-라 로슈 아게 당뇨병 치료에 유용한 ｐｐａｒ 작동제로서 ｎ-치환된-1ｈ-인돌-5-프로파이온산 화합물
JP4384052B2 (ja) * 2002-11-25 2009-12-16 エフ．ホフマン−ラ ロシュ アーゲー インドリル誘導体
AU2003300959A1 (en) * 2002-12-17 2004-07-22 Evolution Robotics, Inc. Systems and methods for visual simultaneous localization and mapping
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP2029564A4 (en) * 2006-05-22 2010-01-13 Vanda Pharmaceuticals Inc TREATMENT OF DEPRESSIVE DISORDERS
CA2666293C (en) * 2006-05-22 2017-01-10 Vanda Pharmaceuticals, Inc. Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders
BRPI0810997A2 (pt) * 2007-04-26 2015-01-27 Takeda Pharmaceutical Composto, pró-droga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono em um mamífero, e, uso do composto
US7964430B2 (en) * 2007-05-23 2011-06-21 Applied Materials, Inc. Silicon layer on a laser transparent conductive oxide layer suitable for use in solar cell applications
CA2698540A1 (en) * 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
EP2453891A1 (en) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2287159A1 (en) * 2009-07-29 2011-02-23 V.Mane Fils New bicyclic dioxanes, their preparation and their use as organoleptic compounds
US8268848B2 (en) * 2010-09-22 2012-09-18 Eisai R&D Management Co., Ltd. Cyclopropane compound
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
ES2897671T3 (es) 2012-01-26 2022-03-02 Vanda Pharmaceuticals Inc Sincronización del ritmo circadiano desincrónico del cortisol
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
ES2648987T3 (es) 2012-05-18 2018-01-09 Vanda Pharmaceuticals Inc. Metabolitos de (1R-trans)-N-[[2-(2,3-dihidro-4-benzofuranil)ciclopropil]metil]propanamida
EP2884275A4 (en) * 2012-07-10 2016-04-13 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF STRESS-RELATED HARNINE CONTINENCE OR MIXED INCONTINENCE AND METHOD FOR SCREENING COMPOUNDS FOR INTRODUCTION TO THIS PHARMACEUTICAL COMPOSITION
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
CN105142630A (zh) 2012-12-18 2015-12-09 万达制药公司 昼夜节律紊乱的治疗
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
WO2015047113A1 (en) * 2013-09-30 2015-04-02 Polfarmex S.A. Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as η1-receptor antagonists
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
JP6921534B2 (ja) * 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高純度医薬品等級タシメルテオン
FI3188727T3 (fi) 2014-09-02 2023-02-20 Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi
CN104327022B (zh) * 2014-10-17 2015-12-02 苏州明锐医药科技有限公司 他司美琼的制备方法
CN104402849B (zh) * 2014-11-11 2016-11-09 苏州莱克施德药业有限公司 他司美琼中间体的新制备工艺
CN106588841B (zh) * 2015-10-19 2019-01-25 富乐马鸿凯（大连）医药有限公司 合成2,3-二氢-1-苯并呋喃-4-甲醛的方法
RU2018142019A (ru) 2016-05-06 2020-06-08 ФИЗИШН`С СИЛ, ЭлЭлСи Валериановая композиция и соответствующие способы
CN105949153B (zh) * 2016-05-10 2018-03-02 浙江工业大学 一种他司美琼的合成方法
CN107365288A (zh) * 2016-05-12 2017-11-21 浙江京新药业股份有限公司 他司美琼的晶型
US9944616B2 (en) 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
CN106543119B (zh) * 2016-09-22 2019-07-26 浙江工业大学 一种光学纯他司美琼的制备方法
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018149940A1 (en) 2017-02-17 2018-08-23 Quimica Sintetica, S. A. Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process
ES2965488T3 (es) 2017-08-02 2024-04-15 Vanda Pharmaceuticals Inc Uso de tasimelteón para el tratamiento de trastornos afectivos en pacientes mayoritariamente negroafricanos
CN112074268A (zh) 2018-03-04 2020-12-11 万达制药公司 用他司美琼治疗疾病
EP3849531A1 (en) * 2018-09-12 2021-07-21 Vanda Pharmaceuticals Inc. Improving sleep or post-sleep performance
WO2021003086A1 (en) 2019-06-29 2021-01-07 Vanda Pharmaceuticals Inc. Tasimelteon use in treating sleep aberrations
CA3161975A1 (en) 2019-12-13 2021-06-17 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2667316B1 (fr) * 1990-10-02 1994-09-16 Roussel Uclaf Nouveaux derives du benzofuranne, leur procede de preparation et leur application comme pesticides.
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
CA2176854A1 (en) * 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
TR199802318T2 (xx) * 1996-05-14 1999-03-22 Glaxo Group Limited Kronobiyolojik maddeler olarak benzofuranlar ve benzopiranlar.

Also Published As

Publication number Publication date
IL129999A (en) 2004-06-20
ATE281833T1 (de) 2004-11-15
HUP0000695A2 (hu) 2001-05-28
TW476758B (en) 2002-02-21
JP2001505916A (ja) 2001-05-08
CZ199199A3 (cs) 1999-09-15
NO321450B1 (no) 2006-05-15
DK1027043T3 (da) 2005-01-10
CA2274183C (en) 2006-10-24
DE69731562T2 (de) 2005-11-24
CA2274183A1 (en) 1998-06-18
EP1027043A1 (en) 2000-08-16
US5856529A (en) 1999-01-05
AR010346A1 (es) 2000-06-07
CN1239886A (zh) 1999-12-29
HUP0000695A3 (en) 2002-09-30
NO992804D0 (no) 1999-06-09
BR9713690A (pt) 2000-05-02
CZ297673B6 (cs) 2007-02-28
EP1027043A4 (en) 2002-02-20
BR9713690B1 (pt) 2009-08-11
AU719994B2 (en) 2000-05-18
PL190499B1 (pl) 2005-12-30
PL333950A1 (en) 2000-01-31
ZA9711051B (en) 1999-06-09
JP4290765B2 (ja) 2009-07-08
WO1998025606A1 (en) 1998-06-18
CN1152679C (zh) 2004-06-09
EP1027043B1 (en) 2004-11-10
PT1027043E (pt) 2005-02-28
DE69731562D1 (de) 2004-12-16
HK1029947A1 (en) 2001-04-20
RU2190609C2 (ru) 2002-10-10
HU226524B1 (en) 2009-03-30
CY2501B1 (en) 2005-09-02
IL129999A0 (en) 2000-02-29
NZ335910A (en) 2000-11-24
US6060506A (en) 2000-05-09
KR100499106B1 (ko) 2005-07-01
KR20000069396A (ko) 2000-11-25
AU5598598A (en) 1998-07-03
US5981571A (en) 1999-11-09
ES2230626T3 (es) 2005-05-01

Similar Documents

Publication Publication Date Title
DK1027043T3 (da) Benzodioxol-, benzofuran-, dihydrobenzofuran- og benzodioxanmelatonerge midler
ATE334125T1 (de) (benzodioxan, benzofuran, oder benzopyran) derivate mit fundic entspannungseigenschaften
PT1173431E (pt) Metodo de preparacao do citalopram
DK0901483T3 (da) Benzofuraner og benzopyraner som kronobiologiske midler
ID23872A (id) Komposisi farmasi padat yang mengandung turunan benzofuran
KR950700288A (ko) 5-에이취티4 길항제로서의 벤조피란, 벤조티오피란 및 벤조푸란 유도체(Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists)
DK1437359T3 (da) Hidtil ukendte 3,6-hemiketaler fra 9a-azalidklassen
BR9607698A (pt) Absorvente higiênico composto com formato anatômico
FI962419A0 (fi) Ringoskillator med hoeg hastighet
YU10499A (sh) Supstituisani 1,2,3,4-tetrahidro-2-dibenzofuranamini i 2-aminociklohepta /b/benzofurani
DK1187829T3 (da) Aminoalkylsubstituerede (benzodioxan, benzofuran eller benzopyran) derivater
DK0814804T3 (da) Substituerede benzopyraner
KR960036038U (ko) 모자의 장식용구
FI980993A0 (fi) Betoni/teräs-liittorakenteinen leukapalkki
SE9600813D0 (sv) Dynamisk hantel
KR970059516U (ko) 마우스용 패드
SE9603955D0 (sv) Ny generator
FI963442A0 (fi) Laparakenne salibandy- tai vastaava mailaa varten
KR980003227U (ko) 공사장용 안전 그물망
KR970050425U (ko) 인터버의 케이스
BR7600275U (pt) Lixeira segmentada
FI964199A (fi) Suojarakenne
DE69719819T2 (de) Anatomisch geformter operationshandschuh
KR970053221U (ko) 모자
KR970053222U (ko) 모자

Legal Events

Date Code Title Description
MK1K Patent expired